Johnson &Johnson’s consumer health product business again provides a “growth annuity” as a reliable revenue driver even when sales slump in the more volatile Rx drug and medical device markets, says J&J Worldwide Group Chairman Sandra Peterson.
J&J expects its consumer business, which includes the Tylenol, Motrin and Zyrtec OTC brands manufactured by its McNeil Consumer Healthcare subsidiary, to grow more robust as the firm continues returning recalled products to stores,